Correction to: British Journal of Cancer (2019) 121, 904–911; https://doi.org/10.1038/s41416-019-0612-5, published online 1 November 2019
Since the publication of this paper the authors noticed that an error was made in coding some trastuzumab doses as being dispensed for metastatic disease, when they were actually dispensed for early stage disease. This affected the calculation of the overall recurrence rate and yearly disease-free survival rates, but does not alter the conclusions of the paper. The adjusted numbers differ from the published results by 0.1–0.2%. This has been corrected below.
Recurrence
By 30 June 2016, 1027 patients (7.0%) received at least one dispensing of trastuzumab for metastatic HER2-positive breast cancer. Figure 1 describes annual RFS rates for patients commencing trastuzumab between 2007 and 2016.
Annual overall and recurrence-free survival probabilities (n = 14644) of patients still in follow-up.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tang, M., Schaffer, A., Kiely, B.E. et al. Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). Br J Cancer 123, 868 (2020). https://doi.org/10.1038/s41416-020-0908-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-020-0908-5
